Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia
- PMID: 11260227
- DOI: 10.1034/j.1399-0004.2001.590306.x
Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia
Abstract
Individuals from a large North American population were screened for the presence of the mutation in the alpha1 subunit of the voltage-dependent calcium channel (CACNA1S) that has recently been associated with malignant hyperthermia (MH). This Arg1086His mutation was screened for in 154 MH normal (MHN) individuals and 112 MH susceptible (MHS) individuals, who were diagnosed by the North American protocol of the in vitro contracture test. PCR and restriction enzyme analysis was used to test for the mutation. The Arg1086His mutation in the CACNA1S was not found in any of the MHN individuals. In contrast, two related individuals (grandfather and grandson, father and son of the MH proband) among the MHS group exhibited this mutation. However, a third MHS individual in the same family (granddaughter, cousin of the grandson) did not exhibit this mutation. These results indicate that this mutation may be associated with MH in this family. Genetic alterations in the CACNA1S associated with MH are present in approximately 1% of this North American MHS population.
Similar articles
-
Failure to identify the ryanodine receptor G1021A mutation in a large North American population with malignant hyperthermia.Clin Genet. 1998 Oct;54(4):358-61. doi: 10.1034/j.1399-0004.1998.5440417.x. Clin Genet. 1998. PMID: 9831351
-
Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1).Anesthesiology. 2001 Sep;95(3):716-25. doi: 10.1097/00000542-200109000-00026. Anesthesiology. 2001. PMID: 11575546
-
[In vitro contracture test and gene typing in diagnosing malignant hyperthermia. Each as an appropriate complement to the other method].Anaesthesist. 2000 Feb;49(2):113-20. doi: 10.1007/s001010050017. Anaesthesist. 2000. PMID: 10756965 Clinical Trial. German.
-
Pharmacogenetics and pathophysiology of CACNA1S mutations in malignant hyperthermia.Physiol Genomics. 2017 Feb 1;49(2):81-87. doi: 10.1152/physiolgenomics.00126.2016. Epub 2016 Dec 23. Physiol Genomics. 2017. PMID: 28011884 Review.
-
Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a retrospective cohort study and updated systematic review.Can J Anaesth. 2017 Jul;64(7):736-743. doi: 10.1007/s12630-017-0865-5. Epub 2017 Mar 21. Can J Anaesth. 2017. PMID: 28326467 Review. English.
Cited by
-
Neurological channelopathies.Postgrad Med J. 2005 Jan;81(951):20-32. doi: 10.1136/pgmj.2004.022012. Postgrad Med J. 2005. PMID: 15640425 Free PMC article. Review.
-
PharmGKB summary: very important pharmacogene information for CACNA1S.Pharmacogenet Genomics. 2020 Feb;30(2):34-44. doi: 10.1097/FPC.0000000000000393. Pharmacogenet Genomics. 2020. PMID: 31851124 Free PMC article.
-
A reconstituted depolarization-induced Ca2+ release platform for validation of skeletal muscle disease mutations and drug discovery.J Gen Physiol. 2022 Dec 5;154(12):e202213230. doi: 10.1085/jgp.202213230. Epub 2022 Nov 1. J Gen Physiol. 2022. PMID: 36318155 Free PMC article.
-
The current status of malignant hyperthermia.J Biomed Res. 2019 May 30;34(2):75-85. doi: 10.7555/JBR.33.20180089. J Biomed Res. 2019. PMID: 32305961 Free PMC article.
-
Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.Anesthesiology. 2018 Jan;128(1):168-180. doi: 10.1097/ALN.0000000000001878. Anesthesiology. 2018. PMID: 28902675 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases